Keliximab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Chimeric (primate/human) |
| Target | CD4 |
| Clinical data | |
| Routes of administration | intravenous |
| ATC code | none |
| Identifiers | |
| CAS Number |
174722-30-6  |
| ChemSpider | none |
 (what is this?) (verify) | |
Keliximab is a monoclonal antibody for the treatment of severe chronic asthma. It suppresses the immune reaction by binding to white blood cells via the protein CD4.[1] The drug is a chimeric antibody from Macaca irus and Homo sapiens.[2]
References
- ↑ Kon, OM; Sihra, BS; Compton, CH; Leonard, TB; Kay, AB; Barnes, NC (1998). "Randomised, dose-ranging, placebo-controlled study of chimeric antibody to CD4 (keliximab) in chronic severe asthma". Lancet. 352 (9134): 1109–13. doi:10.1016/S0140-6736(97)12261-9. PMID 9798587.
- ↑ WHO Drug Information
This article is issued from Wikipedia - version of the 8/12/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.